Literature DB >> 15906066

Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis.

Ivan M Gan1, Luana C Ugahary, Jaap T van Dissel, Jan C van Meurs.   

Abstract

PURPOSE: To study intravitreal dexamethasone and vancomycin concentrations, when used together in patients with suspected postoperative bacterial endophthalmitis. Animal studies had suggested that dexamethasone might decrease the concentration of vancomycin.
DESIGN: Prospective randomized clinical trial in a tertiary referral center.
METHODS: Twenty-nine consecutive patients with suspected postoperative bacterial endophthalmitis underwent a vitreous biopsy followed by intravitreal injection of antibiotics (0.2 mg vancomycin, 0.05 mg gentamicin) and 400 mug dexamethasone or placebo. After 3-4 days, the intravitreal injection of antibiotics and dexamethasone or placebo was repeated. In 18 patients, a second biopsy was taken for repeat culture and measurement of vancomycin and dexamethasone concentrations.
RESULTS: In 20/29 patients (69%) the first vitreous cultures were positive; the second culture was negative in all cases. Thirteen out of 29 patients received dexamethasone. Dexamethasone concentrations showed an average of 25 ng/ml 3 days after injection, with an estimated half-life of 5.5 h. Vancomycin concentrations in patients given dexamethasone tended to be higher compared with those in the placebo group (P=0.061).
CONCLUSION: Intravitreal dexamethasone does not lead to decreased vancomycin concentrations, when given simultaneously in the treatment of patients with suspected bacterial endophthalmitis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15906066     DOI: 10.1007/s00417-005-1182-1

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  10 in total

1.  Intraocular dexamethasone produces a harmful effect on treatment of experimental Staphylococcus aureus endophthalmitis.

Authors:  T A Meredith; H E Aguilar; C Drews; A Sawant; S Gardner; L A Wilson; H E Grossniklaus
Journal:  Trans Am Ophthalmol Soc       Date:  1996

2.  Intravitreal dexamethasone effect on intravitreal vancomycin elimination in endophthalmitis.

Authors:  S S Park; R V Vallar; C H Hong; S von Gunten; K Ruoff; D J D'Amico
Journal:  Arch Ophthalmol       Date:  1999-08

3.  Dexamethasone in adults with bacterial meningitis.

Authors:  Jan de Gans; Diederik van de Beek
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

Review 4.  Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions.

Authors:  Michelle C Callegan; Michael Engelbert; David W Parke; Bradley D Jett; Michael S Gilmore
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

5.  Visual outcomes following the use of intravitreal steroids in the treatment of postoperative endophthalmitis.

Authors:  G K Shah; J D Stein; S Sharma; A Sivalingam; W E Benson; C D Regillo; G C Brown; W Tasman
Journal:  Ophthalmology       Date:  2000-03       Impact factor: 12.079

6.  Intravitreal vancomycin and gentamicin concentrations in patients with postoperative endophthalmitis.

Authors:  I M Gan; J T van Dissel; W H Beekhuis; W Swart; J C van Meurs
Journal:  Br J Ophthalmol       Date:  2001-11       Impact factor: 4.638

7.  Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study.

Authors:  T Das; S Jalali; V K Gothwal; S Sharma; T J Naduvilath
Journal:  Br J Ophthalmol       Date:  1999-09       Impact factor: 4.638

8.  Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection.

Authors:  H W Kwak; D J D'Amico
Journal:  Arch Ophthalmol       Date:  1992-02

9.  Evaluation of therapeutic measures for treating endophthalmitis caused by isogenic toxin-producing and toxin-nonproducing Enterococcus faecalis strains.

Authors:  B D Jett; H G Jensen; R V Atkuri; M S Gilmore
Journal:  Invest Ophthalmol Vis Sci       Date:  1995-01       Impact factor: 4.799

10.  Effects of intravitreal dexamethasone on concentration of intravitreal vancomycin in experimental methicillin-resistant Staphylococcus epidermidis endophthalmitis.

Authors:  M A Smith; J A Sorenson; C Smith; M Miller; M Borenstein
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

  10 in total
  19 in total

1.  Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis).

Authors:  Baruch D Kuppermann; Leandro Cabral Zacharias; M Cristina Kenney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

Review 2.  Targets of immunomodulation in bacterial endophthalmitis.

Authors:  Frederick C Miller; Phillip S Coburn; Mursalin Md Huzzatul; Austin L LaGrow; Erin Livingston; Michelle C Callegan
Journal:  Prog Retin Eye Res       Date:  2019-05-28       Impact factor: 21.198

Review 3.  A Review of the Role of Intravitreal Corticosteroids as an Adjuvant to Antibiotics in Infectious Endophthalmitis.

Authors:  Dawn Ching Wen Ho; Aniruddha Agarwal; Cecilia S Lee; Jay Chhablani; Vishali Gupta; Manoj Khatri; Jayabalan Nirmal; Carlos Pavesio; Rupesh Agrawal
Journal:  Ocul Immunol Inflamm       Date:  2016-11-16       Impact factor: 3.070

4.  Persistently Vitreous Culture-Positive Exogenous Bacterial Endophthalmitis.

Authors:  Ella H Leung; Ajay E Kuriyan; Harry W Flynn; Darlene Miller; Laura C Huang
Journal:  Am J Ophthalmol       Date:  2016-02-26       Impact factor: 5.258

Review 5.  Evidence for and against intravitreous corticosteroids in addition to intravitreous antibiotics for acute endophthalmitis.

Authors:  Diem K Bui; Petros E Carvounis
Journal:  Int Ophthalmol Clin       Date:  2014

6.  Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide.

Authors:  Chengyun Wang; Huiyuan Hou; Kaihui Nan; Michael J Sailor; William R Freeman; Lingyun Cheng
Journal:  Exp Eye Res       Date:  2014-11-05       Impact factor: 3.467

7.  New Drugs and New Posterior Delivery Methods in CME.

Authors:  João Rafael de Oliveira Dias; Renata Portella Nunes; Raquel Goldhardt
Journal:  Curr Ophthalmol Rep       Date:  2017-04-07

Review 8.  Bacterial endophthalmitis in the age of outpatient intravitreal therapies and cataract surgeries: host-microbe interactions in intraocular infection.

Authors:  Ama Sadaka; Marlene L Durand; Michael S Gilmore
Journal:  Prog Retin Eye Res       Date:  2012-04-11       Impact factor: 21.198

Review 9.  The therapeutic potential of intraocular depot steroid systems: developments aimed at prolonging duration of efficacy.

Authors:  Martin M Nentwich; Michael W Ulbig
Journal:  Dtsch Arztebl Int       Date:  2012-09-14       Impact factor: 5.594

10.  Toward improving therapeutic regimens for Bacillus endophthalmitis.

Authors:  Brandt J Wiskur; Michael L Robinson; Allison J Farrand; Billy D Novosad; Michelle C Callegan
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.